## FORBES PHARMACY SUBLOCADE REFERRAL

PHONE 412.246.6160 FAX 855.683.0160 EMAIL forbes\_pharm@upmc.edu



In order to initiate Sublocade treatment, please send a valid prescription to Forbes Pharmacy along with a completed referral form.

REFERRAL SOURCE							
Name/Title of Person Completing Form:				Date:			
PATIENT INFORMATION							
Last Name: First N		Name:		DOB:		Sex: M F	Facility:
Address:		City:				State:	ZIP:
Cell Phone:	Home Phone:			Room/Unit N		lumber (Inpatient):	
Emergency Contact:		Phone Number:					
INJECTION PLAN							
Outpatient Injection		☐ CPCDS ☐ Magee ☐ Mercy ☐ NATP ☐ Other Clinic Contact (Name & Phone Number)					
One-Time Day of Discharge Injection		Location Follow-Up Clinic (Name & Phone Number)					
In accordance with the REMS, Sublocade injection may only be delivered to a healthcare setting and is never dispensed to a patient directly. Sublocade injection will only be used for the patient it is ordered and will NOT be transported to any other location/office/person.							
			,			,, 011100, p.013011.	
CLINICAL INFORMATION							
CLINICAL INFORMATION  Has the patient been treated	- plea:	se include ap	plicabl	le clinical cl	hart no	otes	
	- <i>plea</i> : I with S recom	se include ap Sublocade in th mended 7 day	plicable pli	e clinical cl	hart no YES - [ e-conta	otes Date of Last Injectaining	
Has the patient been treated Has the patient received the	- <i>pleas</i> I with S recom alent o	se include ap Sublocade in th mended 7 day	plicable ne past? s of a bu	e clinical cl NO uprenorphin mucosal bup	hart no YES - I e-conta prenorg	otes Date of Last Injectaining	tion:
Has the patient been treated Has the patient received the product delivering the equiva	- <i>pleas</i> I with S recom alent o	se include ap Sublocade in th mended 7 day	plicable ne past? s of a bu	e clinical cl NO uprenorphin mucosal bup	hart no YES - I e-conta prenorg	otes Date of Last Injec aining bhine?	tion:
Has the patient been treated Has the patient received the product delivering the equiva Current Buprenorphine Prod	- pleas I with S recom alent o Iuct:	se include ap Sublocade in th mended 7 day f 8-24 mg/day	plicable ne past? s of a bu	e clinical cl NO uprenorphin mucosal bup	hart no YES - I e-conta prenorp rphine	Date of Last Inject Baining Chine? Dose & Frequence	tion:
Has the patient been treated Has the patient received the product delivering the equiva Current Buprenorphine Prod Allergies:	- please with Strecome alent of luct:	se include ap Sublocade in th mended 7 day f 8-24 mg/day	plicable past? s of a but of trans Curre	Pe clinical cl NO uprenorphin mucosal bug ent Bupreno	hart no YES - I e-conta prenorg rphine	Date of Last Inject aining phine? Dose & Frequence	tion:
Has the patient been treated Has the patient received the product delivering the equiva Current Buprenorphine Prod Allergies: Baseline LFTs (AST/ALT) if ava Current Medications (please	- please with Some recommend of the second s	se include ap Sublocade in the mended 7 day f 8-24 mg/day Include update	plicable past? s of a but of trans Curre	e clinical cl NO uprenorphin- mucosal bug ent Buprenor Scheduled cation list wi	hart no YES - I e-conta prenorg rphine Injection	Date of Last Inject aining phine? Dose & Frequence	tion:  NO YES  Ey:

## PRESCRIPTION INFORMATION

Please send an electronic prescription to UPMC Forbes Pharmacy ( 3501 Forbes Ave, Oxford Buillding, Room 756)

The recommended dose of SUBLOCADE is 300 mg SQ initially at Months 1 & 2, followed by 100 mg monthly maintenance doses. Increasing the maintenance dose to 300 mg monthly may be considered for patients in which the benefits outweigh the risks. For patients who achieve symptom control on lower doses of oral BUP (8-18 mg/day), 100 mg can be used for the second initiation dose Please see the SUBLOCADE Full Prescribing Information, including Boxed Warning, at sublocadehcp.com

- For abdominal subcutaneous injection only. Do not administer intravenously or intramuscularly.
- Examine the injection site for signs of infection or evidence of tampering or attempts to remove the depot.
- Prescription use of this product is limited by the Drug Addiction Treatment Act (DATA) to prescribers who are authorized to treat opioid dependence and are DATA 2000 waivered.
- Sublocade may only be delivered to a healthcare setting and is NEVER dispensed to a patient directly
- Serious harm or death could result if administered intravenously. SUBLOCADE forms a solid mass upon contact with body fluids and may cause occlusion, local tissue damage and thrombo-embolic events, including life-threatening pulmonary emboli, if administered intravenously
- Because of the risk of serious harm or death that could result from intravenous self-administration, SUBLOCADE is only available through a restricted program called the SUBLOCADE REMS Program. Healthcare settings and pharmacies that order and dispense SUBLOCADE must be certified in this program and comply with the REMS requirements.